These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24970900)

  • 1. Systematic review: Monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD.
    Dulai PS; Siegel CA; Colombel JF; Sandborn WJ; Peyrin-Biroulet L
    Gut; 2014 Dec; 63(12):1843-53. PubMed ID: 24970900
    [No Abstract]   [Full Text] [Related]  

  • 2. Mesenchymal stromal cell function is not affected by drugs used in the treatment of inflammatory bowel disease.
    Duijvestein M; Molendijk I; Roelofs H; Vos AC; Verhaar AP; Reinders ME; Fibbe WE; Verspaget HW; van den Brink GR; Wildenberg ME; Hommes DW
    Cytotherapy; 2011 Oct; 13(9):1066-73. PubMed ID: 21846292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there still a room for azathioprine monotherapy in inflammatory bowel disease?
    Bourrier A; Seksik P; Cosnes J
    Curr Drug Targets; 2013 Nov; 14(12):1471-9. PubMed ID: 23574282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical therapy of IBD in 2009.
    Harris A; Feller ER; Shah SA
    Med Health R I; 2009 Mar; 92(3):78-81. PubMed ID: 19385382
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD.
    Dulai PS; Siegel CA; Peyrin-Biroulet L
    Gastroenterol Clin North Am; 2014 Sep; 43(3):441-56. PubMed ID: 25110252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of anti-drug antibodies against tumor necrosis factor inhibitors with addition of immunomodulators: A systematic review and meta-analysis.
    Dhindsa BS; Dhaliwal A; Mashiana HS; Saghir SM; Sayles H; Mubder M; Ohning G; Eichele D
    Indian J Gastroenterol; 2020 Apr; 39(2):153-160. PubMed ID: 32468382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease.
    Johnson CM; Dassopoulos T
    Curr Gastroenterol Rep; 2018 Sep; 20(11):53. PubMed ID: 30267281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate.
    Sandborn WJ
    Am J Gastroenterol; 1996 Mar; 91(3):423-33. PubMed ID: 8633486
    [No Abstract]   [Full Text] [Related]  

  • 11. The role and advances of immunomodulator therapy for inflammatory bowel disease.
    Nielsen OH; Coskun M; Steenholdt C; Rogler G
    Expert Rev Gastroenterol Hepatol; 2015 Feb; 9(2):177-89. PubMed ID: 25101818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal Healing and Deep Remission: A New Treatment Paradigm for Inflammatory Bowel Disease.
    Thomas A; Lodhia N
    J S C Med Assoc; 2015 Jan; 110(4):134-5. PubMed ID: 27141694
    [No Abstract]   [Full Text] [Related]  

  • 13. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.
    Lorenzetti R; Zullo A; Ridola L; Diamanti AP; Laganà B; Gatta L; Migliore A; Armuzzi A; Hassan C; Bruzzese V
    Ann Med; 2014 Nov; 46(7):547-54. PubMed ID: 25105206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance in inflammatory bowel diseases.
    Moreau J; Mas E
    Curr Opin Pharmacol; 2015 Dec; 25():56-61. PubMed ID: 26645664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease.
    Stobaugh DJ; Deepak P
    Ann Pharmacother; 2014 Oct; 48(10):1282-7. PubMed ID: 24982311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety.
    Xu Z; Davis HM; Zhou H
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S60-74. PubMed ID: 25707965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab exerts no direct hepatotoxic effect on HepG2 cells in vitro.
    de Vries HS; de Heij T; Roelofs HM; te Morsche RH; Peters WH; de Jong DJ
    Dig Dis Sci; 2012 Jun; 57(6):1604-8. PubMed ID: 22535279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety.
    Arnott ID; Watts D; Satsangi J
    Pharmacol Res; 2003 Jan; 47(1):1-10. PubMed ID: 12526855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine.
    Nielsen OH; Vainer B; Rask-Madsen J
    Aliment Pharmacol Ther; 2001 Nov; 15(11):1699-708. PubMed ID: 11683683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.
    Ben-Horin S; Waterman M; Kopylov U; Yavzori M; Picard O; Fudim E; Awadie H; Weiss B; Chowers Y
    Clin Gastroenterol Hepatol; 2013 Apr; 11(4):444-7. PubMed ID: 23103905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.